Alexander Belcredi is an accomplished pharmaceutical industry professional with over 10 years of experience, recognized for his expertise in developing phage-based pharmaceuticals to treat bacterial infections. After completing his Master's degree in Modern History and Economics from the University of St. Andrews, he pursued a Master's degree in Business Administration at INSEAD, where his interest in the pharmaceutical industry was piqued. Belcredi began his pharmaceutical career with nine years at BCG, focusing on pharma and medtech industries. In 2017, he co-founded PhagoMed Biopharma GmbH, where he currently holds the position of CEO, overseeing the development of phage therapy treatments for bacterial infections. Additionally, he is the Managing Director for BioNTech R&D Austria at BioNTech SE.